Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization; Guidance for Industry; Correction

---
identifier: "/us/fr/2024-01836"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization; Guidance for Industry; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "2024-01836"
section_name: "Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization; Guidance for Industry; Correction"
positive_law: false
currency: "2024-01-31"
last_updated: "2024-01-31"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2024-01836"
document_type: "notice"
publication_date: "2024-01-31"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "89 FR 6119"
fr_volume: 89
docket_ids:
  - "Docket No. FDA-2024-D-0361"
fr_action: "Correction."
---


#  Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization; Guidance for Industry; Correction

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Correction.

**SUMMARY:**

The Food and Drug Administration (FDA) is correcting a notice that appeared in the *Federal Register* on December 21, 2023. The document announced the availability of a final guidance for industry entitled “Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization.” The document was published with an incorrect docket number. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:**

Maria Clary, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 4638, Silver Spring, MD 20993-0002, 240-402-8615.

**SUPPLEMENTARY INFORMATION:**

In the *Federal Register* of December 21, 2023 (88 FR 88401), in FR Doc. 2023-28092, the following correction is made:

1. On page 88401, in the first column in the header of the document, and in the *ADDRESSES* section, in the second and third lines of the first paragraph, the Docket No. is corrected to read “Docket No. FDA-2024-D-0361.”

Dated: January 25, 2024.

Lauren K. Roth,

Associate Commissioner for Policy.